Treatment of Age-related Macular Degeneration by Fetal Retinal Pigment Epithelial Cells Transplantation

Macular Degeneration Clinical Trial

Official title:

Early Phase I Study of the Safety and Preliminary Efficacy of Human Fetal Retinal Pigment Epithelial(fRPE) Cells Subretinal Transplantation in Age-Related Macular Degeneration(AMD) Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02868424
• Other study ID #: JSPH-fRPE-001
• Status: Active, not recruiting
• Phase: Early Phase 1
• First received: August 8, 2016
• Last updated: June 14, 2017
• Start date: February 13, 2016
• Est. completion date: December 2018

Study information

• Verified date: May 2017
• Source: The First Affiliated Hospital with Nanjing Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Early Phase I Study of the Safety and Preliminary Efficacy of Human Fetal Retinal Pigment Epithelial(fRPE) Cells Subretinal Transplantation in Age-Related Macular Degeneration(AMD) Patients

Description:

This study is a perspective, single-arm and open-labeled investigation of the safety and preliminary efficacy of unilateral subretinal transplantation of fRPE cells in subjects with dry Age-Related Macular Degeneration and non-exudative AMD. The investigators will recruit and enroll 6 patients based on specific inclusive/exclusive criteria. Experimental and self-controlled eye will be determined based on best-corrected visual acuity (BCVA). The eye with BCVA of no more than 20/400 will be determined as experimental eye, which will be divided into 3 groups and undergo subretinal injection of 3 different dosages of fRPE cells (100.000, 200,000 or 500,000) respectively, while the other one (BCVA of more than or equal to 20/400) as control eye, will not receive the surgery.

fRPE cells will be obtained from the fetuses aborted in the Department of Obstetrics and Gynecology in Jiangsu Province Hospital from 2015 to 2018. The obtained fRPE cells will meet specific inclusive/exclusive criteria and conform to Good manufacturing practices (GMP). fRPE will be transplanted by a board-certified vitreoretinal surgeon, which will be administered into the subretinal space of experimental eye through a standard surgical approach.

Immunosuppressive agents will be administered orally to all subjects after transplantation. Dosage and time duration of immunosuppressive agents will be regulated strictly relying on the condition of immune rejection. Subjects will be monitored with ophthalmologic and systemic examinations frequently at regular post-transplant intervals after fRPE cell transplantation.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 6
• Est. completion date: December 2018
• Est. primary completion date: August 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 50 Years to 90 Years

Eligibility

Inclusion Criteria:

• Diagnosis of dry AMD or non-exudative AMD (geographical atrophy>250µm, involving central fovea of macular; or AMD with fibrous disciform scar and maintained stationary for at least 3 months)

• Experimental eye with best-corrected visual acuity (BCVA) of no more than 20/400 and control eye with BCVA of more than or equal to 20/400

• Patients are in good state

• Patient understand and sign the consent form.

Exclusion Criteria:

• Blood routine examination is abnormal (hemoglobin<10gm/dL; blood platelet count<100k/mm³; neutrophil count<1000/mm³)

• Blood biochemistry is abnormal (ALT/AST>1.5; creatinine>1.3mg/dL)

• Experimental eye has optic nerve atrophy caused by glaucoma

• Patients need cataract surgery within a year

• Patients have received cataract surgery and other ocular surgery in recent 3 months

• Experimental eye has retinal detachment, or has received retinal detachment surgery.

• Patients with uveitis and other endophthalmitis

• Patients with other ocular disease affecting vision.

• Patients have participated in clinical study of ocular or systemic drug use in recent 6 months.

• Patients with medical history of malignant cancer (except resected basal cell carcinoma and squamous-cell carcinoma).

• Patients with medical history of myocardial infarction

• Patient with diabetes

• Patient with Parkinson disease or Alzheimer's disease

• Patients are under the treatment of immunosuppressive agent (except intermittent, low-dose corticosteroid treatment).

• Patients with other medical conditions that restricts the compliance and safety of patients, or affects experimental results.

Related Conditions & MeSH terms

• Age Related Macular Degeneration
• AMD
• Macular Degeneration

Intervention

Drug:
• fRPE cells
fRPE cells transplantation directly into the subretinal space of one eye (experimental eye) in a single transplant procedure

Locations

Country	Name	City	State
China	The First Affiliated Hospital with Nanjing Medical University	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
The First Affiliated Hospital with Nanjing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of subjects with adverse events	Descriptive analysis of frequency and types of adverse events experienced by each subject during the study period.	Two years following transplantation
Secondary	Assessment of standardized ETDRS acuity testing	ETDRS stands for Early Treatment Diabetic Retinopathy Study which is designed to accurately measure visual acuity via ETDRS Scoring.	Two years following transplantation
Secondary	Assessment of visual function changes	Assessments will include fluorescein angiography, fundus photography, spectral domain ocular coherence tomography (SD-OCT), microperimetry and multifocal electroretinography.	Two years following transplantation
Secondary	Assessment of systemic condition	Items will include vital signs, electrocardiogram, blood and urine routine examination, tumor marker.	Two years following transplantation